clbr001
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 14, 2020 (NCT04450069)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 1
- Burkitt Lymphoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Myositis · Phase 1
- Sclerosis · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06913608 | Phase 1 | May 31, 2025 | California Institute for Biomedical Research |
| NCT06878248 | Phase 1 | Apr 17, 2025 | Calibr-Skaggs Institute for Innovative Medicines, California Institute for Biomedical Research |
| NCT04488354 | Phase 1 | Jan 21, 2021 | California Institute for Biomedical Research, University of California, San Diego |
| NCT04450069 | Phase 1 | Aug 14, 2020 | California Institute for Biomedical Research, University of California, San Diego |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Biomedical Research | Academic/Hospital | 4 | 4 | 1 | 2020 |
| University of California, San Diego | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Calibr-Skaggs Institute for Innovative Medicines | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1